All In Biotech

Drug Trial Radar · NCT05865028

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

Phase II A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

May 24, 2023

Primary completion

May 24, 2027

Study completion May 24, 2028

Sponsor

Lead sponsor
Elizabeth J FranzmannAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aveta Biomics, Inc.
First posted
May 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess whether APG-157 can reduce the tumor size in participants with the study disease. Another purpose is to find out about the effects of APG-157 on certain tumor markers and oral rinses in participants with the study disease.

Conditions

  • Oropharyngeal Dysplasia
  • Oral Cavity Dysplasia
  • Oral Carcinoma in Situ

Interventions

  • APG-157Drug

    Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic Response RateTime frame: Up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.